Mies R, Lang R, Weidinger G, Welzel D
Arzneimittelforschung. 1983;33(5):771-3.
The antihypertensive efficacy of co-dergocrine mesylate (a mixture of dihydroergocornine mesylate, dihydroergocristine mesylate, and alpha- and beta-dihydroergocryptine mesylates; Hydergin) and its effects on heart rate, plasma catecholamines, catecholamine excretion and plasma prolactin was tested in 12 elderly hypertensive patients. Co-dergocrine mesylate (6 mg or 12 mg, 1 or 2 tablets once a day) caused a significant reduction of the blood pressure during rest and under physical stress without a reactive increase of the heart rate. Plasma norepinephrine and prolactin as well as urinary excretion of norepinephrine and epinephrine were not affected by co-dergocrine mesylate. The therapeutic advantage of co-dergocrine mesylate for the treatment of hypertension in the elderly is discussed.
在12例老年高血压患者中测试了甲磺酸双氢麦角隐亭（甲磺酸二氢麦角柯宁、甲磺酸二氢麦角克碱和甲磺酸α-及β-二氢麦角隐亭的混合物；海得琴）的降压疗效及其对心率、血浆儿茶酚胺、儿茶酚胺排泄和血浆催乳素的影响。甲磺酸双氢麦角隐亭（6毫克或12毫克，每日1次或2次，每次1或2片）可使静息和体力应激时的血压显著降低，且心率无反应性增加。血浆去甲肾上腺素和催乳素以及去甲肾上腺素和肾上腺素的尿排泄不受甲磺酸双氢麦角隐亭影响。讨论了甲磺酸双氢麦角隐亭治疗老年高血压的治疗优势。
